Androgenetic Alopecia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major androgenetic alopecia markets reached a value of US$ 1,737.6 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2,637.1 Million by 2034, exhibiting a growth rate (CAGR) of 3.91% during 2024-2034.
The androgenetic alopecia market has been comprehensively analyzed in IMARC's new report titled "Androgenetic Alopecia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Androgenetic alopecia, also known as pattern hair loss, is a hair loss condition that mainly affects the top and front of the scalp. It is distinguished by hair follicles that gradually decrease in size. This type of patterned loss of hair is commonly known as non-scarring hair loss and has a distinct pattern in both males and females. Androgenetic alopecia originates just above the temples and at the scalp's vertex area in men. A border of hair remains at the sides and back of the head as it proceeds. This condition causes widespread thinning without hairline recession in females, as it does in males, and rarely leads to overall hair loss. Men with androgenetic alopecia can be diagnosed by their appearance, which includes symptoms and indications of male pattern baldness. In contrast, diagnosis in women typically entails a complicated sequence of testing. Further investigation of the differential requires ruling out other causes of hair loss and looking for the usual progressive hair loss pattern of androgenetic alopecia. Additional tests can be performed using trichoscopy and biopsy may also be required to rule out other reasons for hair loss.
The increasing prevalence of severe hair loss and damage owing to sedentary lifestyles, unhealthy eating habits, and growing stress levels is primarily driving the androgenetic alopecia market. In addition to this, the rising incidences of chronic diseases, such as polycystic ovary disease (PCOD), hyperthyroidism, cancer, hypothyroidism, lupus, hypopituitarism, etc., which are associated with hair loss, are also creating a positive outlook for the market. Moreover, the expanding geriatric population, who are more prone to the disease as aging significantly leads to the gradual thinning of hair, is further bolstering the global market. Apart from this, the emerging popularity of low-level laser therapy, a non-pharmacological and non-surgical viable therapeutic procedure for hair restoration, is acting as a significant growth-inducing factor. It also offers the convenience of at-home use and minimizes the need for clinical visits. Additionally, the widespread adoption of off-label and over-the-counter medications coupled with the rising consumption of dietary supplements to prevent and control hair loss is further propelling the market growth. Besides this, several key players are making extensive investments in developing efficient treatment modalities that can provide satisfying and long-term results. This, in turn, is also expected to drive the androgenetic alopecia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the androgenetic alopecia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for androgenetic alopecia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the androgenetic alopecia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the androgenetic alopecia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the androgenetic alopecia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current androgenetic alopecia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the androgenetic alopecia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the androgenetic alopecia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the androgenetic alopecia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the androgenetic alopecia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of androgenetic alopecia ?
What will be the growth rate of patients across the seven major markets?
Androgenetic Alopecia : Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for androgenetic alopecia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the androgenetic alopecia market?
The androgenetic alopecia market has been comprehensively analyzed in IMARC's new report titled "Androgenetic Alopecia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Androgenetic alopecia, also known as pattern hair loss, is a hair loss condition that mainly affects the top and front of the scalp. It is distinguished by hair follicles that gradually decrease in size. This type of patterned loss of hair is commonly known as non-scarring hair loss and has a distinct pattern in both males and females. Androgenetic alopecia originates just above the temples and at the scalp's vertex area in men. A border of hair remains at the sides and back of the head as it proceeds. This condition causes widespread thinning without hairline recession in females, as it does in males, and rarely leads to overall hair loss. Men with androgenetic alopecia can be diagnosed by their appearance, which includes symptoms and indications of male pattern baldness. In contrast, diagnosis in women typically entails a complicated sequence of testing. Further investigation of the differential requires ruling out other causes of hair loss and looking for the usual progressive hair loss pattern of androgenetic alopecia. Additional tests can be performed using trichoscopy and biopsy may also be required to rule out other reasons for hair loss.
The increasing prevalence of severe hair loss and damage owing to sedentary lifestyles, unhealthy eating habits, and growing stress levels is primarily driving the androgenetic alopecia market. In addition to this, the rising incidences of chronic diseases, such as polycystic ovary disease (PCOD), hyperthyroidism, cancer, hypothyroidism, lupus, hypopituitarism, etc., which are associated with hair loss, are also creating a positive outlook for the market. Moreover, the expanding geriatric population, who are more prone to the disease as aging significantly leads to the gradual thinning of hair, is further bolstering the global market. Apart from this, the emerging popularity of low-level laser therapy, a non-pharmacological and non-surgical viable therapeutic procedure for hair restoration, is acting as a significant growth-inducing factor. It also offers the convenience of at-home use and minimizes the need for clinical visits. Additionally, the widespread adoption of off-label and over-the-counter medications coupled with the rising consumption of dietary supplements to prevent and control hair loss is further propelling the market growth. Besides this, several key players are making extensive investments in developing efficient treatment modalities that can provide satisfying and long-term results. This, in turn, is also expected to drive the androgenetic alopecia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the androgenetic alopecia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for androgenetic alopecia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the androgenetic alopecia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the androgenetic alopecia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the androgenetic alopecia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current androgenetic alopecia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the androgenetic alopecia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the androgenetic alopecia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the androgenetic alopecia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the size of the androgenetic alopecia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of androgenetic alopecia ?
What will be the growth rate of patients across the seven major markets?
Androgenetic Alopecia : Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for androgenetic alopecia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the androgenetic alopecia market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANDROGENETIC ALOPECIA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 ANDROGENETIC ALOPECIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANDROGENETIC ALOPECIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 ANDROGENETIC ALOPECIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANDROGENETIC ALOPECIA - UNMET NEEDS
10 ANDROGENETIC ALOPECIA - KEY ENDPOINTS OF TREATMENT
11 ANDROGENETIC ALOPECIA - MARKETED PRODUCTS
11.1 List of Androgenetic Alopecia Marketed Drugs Across the Top 7 Markets
11.1.1 Minoxidil - Tritech Biopharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Finasteride - Merck & Co.
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 ANDROGENETIC ALOPECIA - PIPELINE DRUGS
12.1 List of Androgenetic Alopecia Pipeline Drugs Across the Top 7 Markets
12.1.1 Dalosirvat - Biosplice Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ifidancitinib - Aclaris Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Clascoterone - Cassiopea
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Finasteride (Topical) - Dong-A ST
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 FOL 100 - Follicle Pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. ANDROGENETIC ALOPECIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 ANDROGENETIC ALOPECIA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Androgenetic Alopecia - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Androgenetic Alopecia - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Androgenetic Alopecia - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Androgenetic Alopecia - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Androgenetic Alopecia - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Androgenetic Alopecia - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Androgenetic Alopecia - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Androgenetic Alopecia - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Androgenetic Alopecia - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Androgenetic Alopecia - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Androgenetic Alopecia - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Androgenetic Alopecia - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Androgenetic Alopecia - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Androgenetic Alopecia - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Androgenetic Alopecia - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Androgenetic Alopecia - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Androgenetic Alopecia - Access and Reimbursement Overview
15 ANDROGENETIC ALOPECIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 ANDROGENETIC ALOPECIA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 ANDROGENETIC ALOPECIA - INTRODUCTION
4.1 Overview
4.2 Epidemiology (2018-2023) and Forecast (2024-2034)
4.3 Market Overview (2018-2023) and Forecast (2024-2034)
4.4 Competitive Intelligence
5 ANDROGENETIC ALOPECIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 ANDROGENETIC ALOPECIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
8 ANDROGENETIC ALOPECIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 ANDROGENETIC ALOPECIA - UNMET NEEDS
10 ANDROGENETIC ALOPECIA - KEY ENDPOINTS OF TREATMENT
11 ANDROGENETIC ALOPECIA - MARKETED PRODUCTS
11.1 List of Androgenetic Alopecia Marketed Drugs Across the Top 7 Markets
11.1.1 Minoxidil - Tritech Biopharmaceuticals
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Finasteride - Merck & Co.
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report.
12 ANDROGENETIC ALOPECIA - PIPELINE DRUGS
12.1 List of Androgenetic Alopecia Pipeline Drugs Across the Top 7 Markets
12.1.1 Dalosirvat - Biosplice Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Ifidancitinib - Aclaris Therapeutics
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Clascoterone - Cassiopea
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Finasteride (Topical) - Dong-A ST
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 FOL 100 - Follicle Pharma
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report.
13. ANDROGENETIC ALOPECIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 ANDROGENETIC ALOPECIA - MARKET SCENARIO
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1 Androgenetic Alopecia - Market Size
14.2.1.1 Market Size (2018-2023)
14.2.1.2 Market Forecast (2024-2034)
14.2.2 Androgenetic Alopecia - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2018-2023)
14.2.2.2 Market Forecast by Therapies (2024-2034)
14.3 Market Scenario - United States
14.3.1 Androgenetic Alopecia - Market Size
14.3.1.1 Market Size (2018-2023)
14.3.1.2 Market Forecast (2024-2034)
14.3.2 Androgenetic Alopecia - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2018-2023)
14.3.2.2 Market Forecast by Therapies (2024-2034)
14.3.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1 Androgenetic Alopecia - Market Size
14.4.1.1 Market Size (2018-2023)
14.4.1.2 Market Forecast (2024-2034)
14.4.2 Androgenetic Alopecia - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2018-2023)
14.4.2.2 Market Forecast by Therapies (2024-2034)
14.4.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1 Androgenetic Alopecia - Market Size
14.5.1.1 Market Size (2018-2023)
14.5.1.2 Market Forecast (2024-2034)
14.5.2 Androgenetic Alopecia - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2018-2023)
14.5.2.2 Market Forecast by Therapies (2024-2034)
14.5.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1 Androgenetic Alopecia - Market Size
14.6.1.1 Market Size (2018-2023)
14.6.1.2 Market Forecast (2024-2034)
14.6.2 Androgenetic Alopecia - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2018-2023)
14.6.2.2 Market Forecast by Therapies (2024-2034)
14.6.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1 Androgenetic Alopecia - Market Size
14.7.1.1 Market Size (2018-2023)
14.7.1.2 Market Forecast (2024-2034)
14.7.2 Androgenetic Alopecia - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2018-2023)
14.7.2.2 Market Forecast by Therapies (2024-2034)
14.7.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1 Androgenetic Alopecia - Market Size
14.8.1.1 Market Size (2018-2023)
14.8.1.2 Market Forecast (2024-2034)
14.8.2 Androgenetic Alopecia - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2018-2023)
14.8.2.2 Market Forecast by Therapies (2024-2034)
14.8.3 Androgenetic Alopecia - Access and Reimbursement Overview
14.9 Market Scenario - Japan
14.9.1 Androgenetic Alopecia - Market Size
14.9.1.1 Market Size (2018-2023)
14.9.1.2 Market Forecast (2024-2034)
14.9.2 Androgenetic Alopecia - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2018-2023)
14.9.2.2 Market Forecast by Therapies (2024-2034)
14.9.3 Androgenetic Alopecia - Access and Reimbursement Overview
15 ANDROGENETIC ALOPECIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
16 ANDROGENETIC ALOPECIA MARKET - SWOT ANALYSIS
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats
17 APPENDIX
